The goal of RPCI's Preclinical Imaging Resource (PIR) is to advance small animal imagingmethodology at the molecular, cellular and biosystem level. This is accomplished by facilitating developmentof novel basic science and clinical research, promoting advances in biotechnology, fostering development ofnew Pharmaceuticals and assessing in vivo drug delivery and therapeutic efficacy. The PIR currently offerscustomized magnetic resonance (MR) protocols designed to answer specific questions related to: (i) cancerdetection, (ii) tumor vascular function, (iii) therapeutic response, (iv) animal phenotyping and (v)pharmacokinetic /pharmacodynamic modeling. In addition, the Resource provides whole-body fluorescenceimaging of live animals and facilitates collaborative microPET research in conjunction with the University atBuffalo (UB).
The aim i s to provide readily available access and training to noninvasive, state-of-the-art invivo imaging technologies at an affordable cost to CCSG members. The PIR is available 24 hours/day, 7days/week.Three general types of MR services are offered: (a) instrumentation and expertise to acquire highresolution (< 50 urn2 in-plane spatial and < 100 ms temporal) heteronuclear imaging and spectroscopy data,(b) expertise and software for quantitative image analysis and (c) visualization of 2D and 3D data sets forprobing structural/functional relationships. MR instrumentation includes a 4.7 T wide bore (33 cm) magnetincorporating Bruker's Avance platform with ParaVision 4.0 OS, shielded Accustar gradients and digitalsystem electronics. The MR system represents the highest magnetic field strength scanner available within200 miles of RPCI. Recently expanded services include whole body in vivo optical and multispectralfluorescence imaging. Intravital Microscopy (IVM) using a MR compatible window chamber is also availablefor fluorescence imaging with MR validation. Data acquisition, hardcopy, display, qualitative/quantitativeanalysis and 3D renderings of digitally acquired data sets are offered as chargeback services.The Resource is used by five programs and 99% of users are CCSG members. $65,218 in CCSGsupport is requested, representing 12% of the total operating budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016056-32
Application #
7714431
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-07-28
Project End
2013-04-30
Budget Start
2008-07-28
Budget End
2009-04-30
Support Year
32
Fiscal Year
2008
Total Cost
$54,818
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Li, Qiuhui; Deng, Qu; Chao, Hsueh-Ping et al. (2018) Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun 9:3600
Rossetti, Stefano; Wierzbicki, Andrzej J; Sacchi, Nicoletta (2018) Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: an offbeat approach to target MYC-driven cancer. Oncotarget 9:5016-5031
Mett, V; Komarova, E A; Greene, K et al. (2018) Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene 37:439-449
Long, Mark D; Singh, Prashant K; Russell, James R et al. (2018) The miR-96 and RAR? signaling axis governs androgen signaling and prostate cancer progression. Oncogene :
Kawaguchi, Tstutomu; Yan, Li; Qi, Qianya et al. (2018) Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer. Ann Surg Oncol 25:4037-4046
Vexler, Albert; Yu, Jihnhee; Zhao, Yang et al. (2018) Expected p-values in light of an ROC curve analysis applied to optimal multiple testing procedures. Stat Methods Med Res 27:3560-3576
Mussell, Ashley L; Denson, Kayla E; Shen, He et al. (2018) Loss of KIBRA function activates EGFR signaling by inducing AREG. Oncotarget 9:29975-29984
Hirose, Yuki; Nagahashi, Masayuki; Katsuta, Eriko et al. (2018) Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis. Sci Rep 8:10814
Kesterson, Joshua P; Szender, J Brian; Schaefer, Eric et al. (2018) Evaluation of Association Between Gynecologic Oncology Fellowship Length and a Career in Academic Medicine. J Cancer Educ 33:141-146

Showing the most recent 10 out of 1555 publications